ERC Grant Archives - Institute for Bioengineering of Catalonia

September 4, 2025

CHEMTUBIO, a new ERC project at IBEC to study enzymes with therapeutic potential

Carlos Moreno Yruela, who is currently a researcher at the Swiss Federal Institute of Technology in Lausanne, Switzerland, was selected in the ERC Starting Grants call to develop the CHEMTUBIO project at the Institute for Bioengineering of Catalonia (IBEC). The project will study the chemistry of enzymes that erase microtubule modifications. These enzymes are essential for the functioning of our cells and have shown great promise as potential therapeutic targets for treating cancer, heart disease and neurological disorders.

July 14, 2025

Two IBEC projects receive ERC funding to advance bioinks for 3D printing and cancer therapies

Manuel Salmeron and Xavier Rovira, who are both principal investigators at IBEC, have each been awarded an ERC Proof of Concept Grant. These prestigious grants are awarded by the European Research Council to explore the commercial and social potential of research projects carried out at European institutions. Salmeron’s project, FACTORINK, focuses on designing functional bioinks with biological activity for printing artificial tissues. Meanwhile, Rovira’s project seeks to develop the EVOaware platform, which is designed to address tumour resistance to therapies and accelerate the discovery and development of new cancer treatments.

January 23, 2025

INTROPY: A new approach to cancer therapy by inhibiting mechanotransduction

IBEC senior researcher Pere Roca-Cusachs has been awarded an ERC Proof of Concept Grant. This is a prestigious grant awarded by the European Research Council to explore the commercial and societal potential of research projects carried out at European institutions. Roca-Cusachs’ project, INTROPY, focuses on the inhibition of mechanotransduction as a potential therapy against cancer or fibrosis.

December 4, 2024December 3, 2024

IBEC scientist César Rodriguez-Emmenegger awarded prestigious ERC Consolidator Grant

IBEC’s Principal Investigator César Rodriguez-Emmenegger has been awarded an ERC Consolidator Grant. This prestigious European funding supports scientists in the consolidation phase of their research teams, allowing them to pursue innovative scientific ideas. The €2 million over five years will allow Rodriguez-Emmenegger and his team to develop Phagocytic Synthetic Cells (PSCs) to fight antibiotic-resistant pathogens.

September 5, 2024

Researcher Irene Marco Rius awarded prestigious European ERC Starting Grant

IBEC Principal Investigator Irene Marco Rius has been selected for the European Research Council (ERC) Starting Grant call to carry out her project ‘LIFETIME’. The project focuses on the study of individual cancer metabolism, which is crucial for less invasive early diagnosis and personalised treatments.

January 8, 2024September 6, 2023

The ERC supports the “SpaceClones” project to understand the clonal evolution of tumors

Xavier Rovira Clavé, currently a researcher at Stanford University’s School of Medicine, has been awarded the “Starting Grant” from the European Research Council (ERC) to carry out his project “SpaceClones” … Read more

September 6, 2023July 27, 2023

Samuel Sánchez Receives ERC Proof of Concept Grant to Target Mucinous Tumors with his Nanorobots

Samuel Sánchez has successfully secured an “ERC Proof of Concept” grant, provided by the European Research Council (ERC), to explore the application of his nanorobots in the treatment of mucus-secreting tumors. This prestigious grant enables researchers to assess the feasibility and potential for knowledge transfer of their research projects.

May 11, 2023May 11, 2023

Last 23rd and 24th of June took place the European Research and Innovation Days, where Nuria Montserrat was invited to share her research and personal experiences in a high-level panel about “COVID-19: lessons learnt, preparedness and resilience”. The event was opened by Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth and was moderated chaired by Philip Campbell, Editor-in-Chief Springer Nature.